Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12187769
Cell
granted -
US 12186349
Compositions and methods for C. difficile treatment
granted -
US 12186363
Compositions and methods for dengue virus chimeric constructions in vaccines
granted -
US 12186378
Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists
granted -
US 12186384
Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
granted -
US 12186342
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha
granted -
US 12188005
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
granted -
US 12186313
Pyridazinone compounds and their use as DAAO inhibitors
granted -
US 12187815
Anti-inflammatory nanofibers
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12188069
Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds
granted -
US 12188926
Stimuli responsive microsphere composites
granted -
US 12187698
Crystalline forms of C21H22Cl2N4O2
granted -
US 12187992
Method and device for early cancer screening
granted -
US 12187804
Multivalent and multispecific 41BB-binding proteins
granted -
US 12187780
Car t-cells comprising inactivated CBL and CBL-B genes
granted -
US 12186306
Methods of treatment for cystic fibrosis
granted -
US 12187779
Anti-human papillomavirus 16 E6 T cell receptors
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12187731
Compounds useful as inhibitors of ATR kinase
granted -
US 12188048
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted -
US 12186285
Compositions and methods of treatment for tinea pedis
granted -
US 12186314
Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 12188072
Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
granted -
US 12188949
Noninvasive method to quantify kidney function and functional decline
granted -
US 12187744
IRAK4 degraders and synthesis thereof
granted -
US 12187762
Dithiolsaccharide mucolytic agents and uses thereof
granted -
US 12188948
Metabolite biomarkers for diseases associated with the contact activation system
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12188060
Messenger RNA encoding Cas9 for use in genome-editing systems
granted -
US 12187746
C26-linked rapamycin analogs as mTOR inhibitors
granted -
US 12187777
Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
granted -
US 12187694
SLC26A3 inhibitors and use thereof
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12186406
Materials and methods for treatment of hereditary haemochromatosis
granted -
US 12186428
Combination taxoid nanoemulsion with immunotherapy in cancer
granted -
US 12186369
Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy
granted -
US 12186324
Imidazopiperazine inhibitors of transcription activating proteins
granted -
US 12186282
Treatment of 22Q11.2 deletion syndrome with cannabidiol
granted -
US 12186375
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
granted -
US 12186330
Compositions for improving cell viability and methods of use thereof
granted -
US 12186368
Compositions and methods for treatment of protease mediated disease
granted -
US 12187848
Compositions and methods for cellular delivery
granted -
US 12186367
Isoform Nell-1 peptide
granted -
US 12187772
IL10 agonists and methods of use thereof
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.